Figure 5
The HECTD3 expression is elevated in breast cancer. (a) The HECTD3 mRNA levels in 30 breast cancer cell lines and four control samples were measured by qRT-PCR. GAPDH was used to normalize the input cDNA. The negative control samples (the average HECTD3 mRNA level was defined as 1.0) are indicated as green bars. Cancer samples (19/30) with the HECTD3 overexpression (>2-fold) are highlighted in red. The cancer samples without the HECTD3 overexpression are represented as blue bars. MB in cell line names is an abbreviation of MDA-MB. (b) The expression of the HECTD3 protein in breast cell lines was determined by WB. β-Actin was used as the loading control. The ERα expression in these cell lines is also shown. (c) The HECTD3 mRNA levels in 48 breast tissues (5 normal and 43 cancer specimens) in different stages. The cDNA levels were normalized by β-actin. (d) HECTD3 protein expression in normal breast tissues and breast carcinomas specimens detected by IHC. Tumor#1 demonstrates diffuse, weak cytoplasmic immunoreactivity (C, 25% of all tumors). Tumor#2 demonstrates diffuse nuclear immunostaining (N, 42% of all tumors). Tumor#3 demonstrates both cytoplasmic and nuclear immunostaining (B, 36% of all tumors). The IHC results from 42 normal and 79 breast cancer samples were summarized in the table below the image
